SCHEMBL19258882

SCHEMBL19258882

NC(=O)c1cnc(C(F)(F)F)[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.41
KMT2A Q03164 1/20 0.41
CFTR P13569 1/20 0.35
HTT P42858 2/20 0.33
MAP2K1 Q02750 1/20 0.33
PDPK1 O15530 1/20 0.33
SCN9A Q15858 1/20 0.33
BAZ2B Q9UIF8 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
HSD17B10 Q99714 1/20 0.32
HSD17B2 P37059 1/20 0.32
ADORA3 P0DMS8 1/20 0.31
TSHR P16473 1/20 0.31
MC4R P32245 1/20 0.31
ADRA1A P35348 1/20 0.31
MC3R P41968 1/20 0.31
CCNC P24863 1/20 0.30
CDK8 P49336 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833726 0.82 PIN1 (0.46) PARP1CFTRHTTKDM4EHPGD
SCHEMBL6104097 0.81 CFTR (0.37) PARP1KMT2ACFTRHTTKDM4E
SCHEMBL11630106 0.77 HSD17B2 (0.44) PARP1KMT2AKDM4EHPGDHSD17B2
SCHEMBL30147609 0.77 PKM (0.38) KMT2ACFTRHTTKDM4EHPGD
SCHEMBL3635860 0.74 KMT2A (0.33) KMT2A
SCHEMBL8308592 0.71 MAP2K1 (0.38) MAP2K1PDPK1SCN9ABAZ2BSMN1; SMN2
SCHEMBL19339784 0.69
SCHEMBL759817 0.69
SCHEMBL10869963 0.68 PIN1 (0.39) MAP2K1PDPK1BAZ2BKDM4ESMN1; SMN2
SCHEMBL6288388 0.67 CTNNB1 (0.47) PARP1KMT2AHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023074847-A1 NOVEL SPIRO COMPOUND 田辺三菱製薬株式会社 2023-05-04 WO disclosed
US-20170233398-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SITEONE THERAPEUTICS, INC. 2017-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170233398-A1 11,13-MODIFIED SAXITOXINS FOR THE TREATMENT OF PAIN SCN11A, SCN10A, SCN3A PARP1 4736/4885KMT2A 3954/4885CFTR 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.